Zithromax (Azithromycin) Patent Expiration, LOE Window & CMS Spending
Zithromax (Azithromycin) by Pfizer: Off-Patent Genericized (AB Competition), 34 AB generics, $417K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N050710 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 34 |
| 2024 CMS Total Public Spend | $417K |
| 2024 Medicare Part D Spend | $20K |
| 2024 Medicaid Spend | $397K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.